Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20172889 | 0.89 | ALDH1A1 (0.34) | POLBMAPTALDH1A1NPSR1 | |
| SCHEMBL20172877 | 0.88 | ACHE (0.37) | ACHEPOLBLMNAMAPTALDH1A1 | |
| SCHEMBL20172875 | 0.87 | CYP1A2 (0.35) | ALDH1A1HSD17B1HSD17B2CYP2A6CYP1A2 | |
| SCHEMBL23967806 | 0.86 | CYP1A2 (0.32) | MAPTCYP2A6CYP1A2NPSR1 | |
| SCHEMBL21020323 | 0.83 | SIGMAR1 (0.34) | POLBALDH1A1TSHRNPSR1 | |
| SCHEMBL20172887 | 0.82 | ALDH1A1 (0.35) | POLBLMNAMAPTALDH1A1CYP1A2 | |
| SCHEMBL20172866 | 0.81 | GPR3 (0.41) | POLBLMNAMAPTALDH1A1HSD17B1 | |
| SCHEMBL20172886 | 0.81 | SIGMAR1 (0.34) | — | |
| SCHEMBL20172915 | 0.81 | HSD17B1 (0.33) | MAPTALDH1A1HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL20172893 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10651411-B2 | Compound and organic light emitting device containing same | LG CHEM, LTD. (KR) | 2020-05-12 | — | — | US | disclosed |
| US-20180145272-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE CONTAINING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180145272-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE CONTAINING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180145272-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE CONTAINING SAME | CRY1, CRY2, OR10J3 | ACHE 337/4885POLB 3877/4885LMNA 4253/4885 |
| US-10651411-B2 | Compound and organic light emitting device containing same | CRY1, CRY2, OR10J3 | ACHE 337/4885POLB 3877/4885LMNA 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.